Medicine and Dentistry
Adjuvant Chemotherapy
7%
Biological Marker
19%
Biopsy
8%
Bladder
49%
Bladder Cancer
50%
Bladder Tumor
9%
Cancer Recurrence
7%
Cancer Specific Survival
22%
Cancer Staging
9%
Carcinoma in Situ
11%
Cell Cycle
8%
Clear Cell Renal Cell Carcinoma
34%
Clinical Stage
8%
Cystectomy
62%
Cystoscopy
8%
Cytotechnology
9%
Disease
37%
Germinoma
8%
Hazard Ratio
13%
Kidney Function
9%
Kidney Transplantation
9%
Kidney Tumour
11%
Lymph Node
19%
Lymph Node Metastasis
6%
Lymphovascular Invasion
15%
Malignant Neoplasm
25%
Metastatic Carcinoma
13%
Multivariate Analysis
7%
Neoadjuvant Chemotherapy
9%
Neoplasm
36%
Nephroureterectomy
24%
Oncology
6%
Overall Survival
10%
Proportional Hazards Model
8%
Prostate Cancer
8%
Protein P53
10%
Radical Nephrectomy
6%
Recurrence Free Survival
10%
Recurrent Disease
36%
Retroperitoneal Lymph Node Dissection
12%
Surgery
9%
Survival Rate
6%
Testis Cancer
10%
Transitional Cell Carcinoma
100%
Transplantation
8%
Transurethral Resection
8%
Tumor Thrombus
8%
Upper Urinary Tract
14%
Urinary Diversion
10%
Urothelial Cancer
8%
Keyphrases
Bladder Cancer
18%
Bladder Transitional Cell Carcinoma
5%
Cancer Mortality
6%
Cancer Outcomes
5%
Cancer-specific Survival
10%
Carcinoma in Situ
6%
Clear Cell Renal Cell Carcinoma (ccRCC)
5%
Confidence Interval
6%
Cystectomy
5%
Cystoscopy
5%
Hazard Ratio
6%
Ki-67
6%
Lymphovascular Invasion
6%
Neoadjuvant Chemotherapy
5%
Nephroureterectomy
12%
Oncological Outcomes
14%
Pathological Stage
6%
Radical Cystectomy
30%
Recurrent Disease
6%
Renal Cell Carcinoma
13%
Renal Transplantation
6%
Transurethral Resection
5%
Tumor
8%
Upper Tract Urothelial Carcinoma
39%
Urothelial Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
14%
Bladder Cancer
36%
Bladder Tumor
5%
Cancer Specific Survival
10%
Carcinoma in Situ
7%
Chemotherapy
14%
Disease
21%
Malignant Neoplasm
15%
Neoplasm
14%
Prostate Cancer
8%
Protein P53
10%
Recurrent Disease
20%
Renal Cell Carcinoma
8%
Transitional Cell Carcinoma
38%
